Light Sciences Oncology Meets a Major Milestone in Aptocine Development with Target Enrollment in Phase 3 MCRC Trial

Company Also Anticipates Phase 3 Results for Aptocine in HCC, Progress in Other Trials, and More Immune-Response Studies

BELLEVUE, WA - February 25, 2010

Light Sciences Oncology, Inc. (LSO) today announced the achievement of a major milestone in its late-stage clinical development of Aptocine^TM (talaporfin sodium) for treatment of solid tumors. LSO's global Phase 3 trial of Aptocine in metastatic colorectal cancer (MCRC) has reached target enrollment of 450 patients at 52 sites. The controlled, randomized MCRC trial is being conducted to assess the progression free survival (PFS) and overall survival (OS) of patients with colorectal cancer with recurrent liver metastases treated with Aptocine plus chemotherapy versus chemotherapy alone. Sufficient events have occurred in enrolled patients to trigger the first of two prospectively defined interim data analyses.

Click here to read LSC's press release.